$CELG

Allogene Therapeutics reported its Q4 2025 earnings, revealing a substantial increase in revenue driven by key therapeutic advancements. The company highlighted progress in its clinical pipeline, particularly in CAR T-cell therapies, and provided positive guidance for the upcoming quarter. Despite the strong results, expenses related to research and development have risen, raising some concerns among investors about profitability. Additionally, Allogene's strategic partnerships were emphasized, potentially strengthening their market position. Overall, the firm aims for continued innovation which could lead to sustained investor interest.